StocksMedium•15 October 2026•
1 min read
Recursion Announces $200M Stock Offering and Sanofi Partnership Milestone
Key Facts
1Recursion announced a $200 million underwritten offering of common stock to institutional investors.
2The company reached a milestone with Sanofi optioning a potential first-in-class immunology development candidate.
3The company revealed updated Phase 1b/2 and Phase 1 clinical data for REC-4881 and REC-1245.
Recursion announced a $200 million underwritten offering of common stock to institutional investors, according to GlobeNewswire. The offering included participation from Janus Henderson Investors and ARK Invest, as the company simultaneously revealed updated Phase 1b/2 and Phase 1 clinical data for its REC-4881 and REC-1245 programs.
The company reached a milestone with Sanofi, which optioned a potential first-in-class immunology development candidate under their ongoing collaboration. In equity markets, SNYNF closed at $78.17 on October 14, 2026, having traded between a day high of $81.34 and a low of $78.17 during that session.